1. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study;Bar-Or;Neurology,2020
2. COVID-19 and MS disease modifying therapies;Berger;Neurol. Neuroimmunol. Neuroinflamm.,2020
3. Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia;Conte;Mult. Scler. Relat. Disord.,2020
4. Effect of ofatumumab on serum immunoglobulin levels and infection risk in relapsing multiple sclerosis patients from the phase 3 ASCLEPIOS I and II trials. poster LB82;De Seze,2020
5. EUA Authorized Serology Test performance. U.S. food and drug administration website. https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/eua-authorized-serology-test-performance. Current as of January 8, 2021. Accessed January 9, 2021.